Published on 13 Jun 2024
Sci & TechHEALTH
SCIENCE
TECHNOLOGY
Antibodies are protective proteins produced by your immune system. They attach to antigens (foreign substances) and remove them from your body.
Broadly neutralizing antibodies (bNAbs) was a type of antibody discovered in the 1990s from a small subset of HIV-infected individuals
They can recognize and block many types of human immunodeficiency virus (HIV) from entering healthy cells.
They may also activate other immune cells to help destroy HIV-infected cells.
Researchers are investigating whether bNAbs could be used to develop a therapeutic HIV vaccine.
The germline-targeting strategy is the one approach where immunologists are using for development of B Cell based HIV vaccine.
Germline-targeting
Germline targeting, uses a series of primer and booster vaccines to train B cells to recognise HIV and produce broadly neutralising antibodies (bnAbs) that can deactivate the virus.
The B Cells, also known as B-lymphocytes are a type of specialised white blood cells that produce antibody proteins in response to pathogens.